世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000039274

多発性硬化症治療薬市場:規模、シェア、動向分析レポート、およびセグメント予測、2024〜2030

Grand View Research Inc.

Multiple Sclerosis Therapeutic Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030

発刊日 2024/08

言語英語

体裁PDF/100ページ

ライセンス/価格100ページ

0000039274

Individual
Team
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

多発性硬化症治療薬の市場シェアと動向分析レポート:薬剤クラス別、投与経路別 (経口、注射用)、流通チャネル別、地域別、セグメント別予測、2024-2030

多発性硬化症治療薬の市場動向

世界の多発性硬化症治療薬の市場規模は、2023年に259億4000万ドルと評価され、2024年から2030年にかけて5.9%のCAGRで成長すると予測されます。市場の成長は、世界的な疾患の蔓延の増加によるものであり、治療の進歩によって、進行を遅らせ、症状をより効果的に管理する疾患修飾療法(DMT)の開発につながりました。

レポート詳細

目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Multiple Sclerosis Therapeutic Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Multiple Sclerosis Therapeutic Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape

Chapter 4. Multiple Sclerosis Therapeutic Market: Drug Class Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Multiple Sclerosis Therapeutic Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
4.3. Immunosuppressants
4.3.1. Immunosuppressants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Immunostimulants
4.4.1. Immunostimulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Multiple Sclerosis Therapeutic Market: Route of Administration Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Multiple Sclerosis Therapeutic Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
5.3. Oral
5.3.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Injectable
5.4.1. Injectable Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Multiple Sclerosis Therapeutic Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Multiple Sclerosis Therapeutic Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacies
6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. E-Commerce
6.5.1. E-Commerce Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Multiple Sclerosis Therapeutic Market: Regional Estimates & Trend Analysis
7.1. Multiple Sclerosis Therapeutic Market Share, By Region, 2023 & 2030 (USD Million)
7.2. North America
7.2.1. North America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Multiple Sclerosis Therapeutic Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Teva Pharmaceutical Industries Ltd.
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. Pfizer Inc.
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Biogen
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Bayer AG
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Sanofi
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. F. Hoffman-La Roche Ltd
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Johnson & Johnson Services, Inc.
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Merck & Co., Inc.
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. Takeda Pharmaceuticals Company Limited.
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Horizon Therapeutics plc
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives

この商品のレポートナンバー

0000039274

TOP